-
公开(公告)号:US10669322B2
公开(公告)日:2020-06-02
申请号:US15780599
申请日:2016-12-16
申请人: BIONTECH RNA PHARMACEUTICALS GMBH , TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GGMBH
IPC分类号: C07K14/54 , C07K14/705 , C12N15/62 , C07K14/525 , A61K38/00
摘要: The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms, pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
-
公开(公告)号:US10301368B2
公开(公告)日:2019-05-28
申请号:US15543566
申请日:2016-01-15
申请人: BioNTech RNA Pharmaceuticals GmbH , Universität Stuttgart , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GGmbH
发明人: Ugur Sahin , Friederike Gieseke , Ronald Backer , Sebastian Kreiter , Roland Kontermann , Klaus Pfizenmaier , Sina Fellermaier , Dafne Müller
IPC分类号: C07K14/52 , C07K14/525 , A61K38/17
摘要: The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms. pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
-
公开(公告)号:US20190276511A1
公开(公告)日:2019-09-12
申请号:US16374503
申请日:2019-04-03
申请人: BioNTech RNA Pharmaceuticals GmbH , Universität Stuttgart , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Univers
发明人: Ugur Sahin , Friederike Gieseke , Ronald Backer , Sebastian Kreiter , Roland Kontermann , Klaus Pfizenmaier , Sina Fellermaier , Dafne Müller
IPC分类号: C07K14/525 , A61K38/17 , C07K14/52
摘要: The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms. pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
-
公开(公告)号:US10808019B2
公开(公告)日:2020-10-20
申请号:US16374503
申请日:2019-04-03
申请人: BioNTech RNA Pharmaceuticals GmbH , Universität Stuttgart , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
发明人: Ugur Sahin , Friederike Gieseke , Ronald Backer , Sebastian Kreiter , Roland Kontermann , Klaus Pfizenmaier , Sina Fellermeier , Dafne Müller
IPC分类号: C07K14/525 , C07K14/52 , A61K38/17
摘要: The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms. pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
-
公开(公告)号:US20210292386A1
公开(公告)日:2021-09-23
申请号:US17262097
申请日:2019-07-19
申请人: BioNTech RNA Pharmaceuticals GmbH , TRON - Translationale Onkologie an der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz
发明人: Ugur Sahin , Mathias Vormehr , Lena Mareen Kranz , Sina Fellermeier-Kopf , Alexander Muik , Friederike Gieseke , Bodo Tillmann , Sonja Witzel
摘要: The invention relates to variants of interleukin-2 (IL2). In one embodiment, the IL2 variants activate effector T cells over regulatory T cells. In particular, the invention relates to a polypeptide comprising a mutein of human IL2 or of a functional variant of human IL2, wherein the human IL2 or functional variant thereof is substituted at at least a position having an acidic or basic amino acid residue in wild type human IL2 that contacts the alpha subunit of the αβγ IL2 receptor complex (I12Kαβγ). Alternatively, the mutein of human IL2 or of a functional variant of human IL2 comprises at least (i) one or more amino acid substitutions which reduce the affinity for the alpha subunit of II_2Kαβγ and (ii) one or more amino acid substitutions which enhance the affinity for II_2Kβγ. The invention also relates to polynucleotides coding for the polypeptides of the invention, host cells comprising the polynucleotides, pharmaceutical compositions comprising the polypeptides, polynucleotides or host cells, therapeutic or prophylactic methods of treatment using the polypeptides, polynucleotides, host cells or pharmaceutical compositions and medical preparations comprising the polypeptides, polynucleotides, host cells or pharmaceutical compositions.
-
公开(公告)号:US20180002392A1
公开(公告)日:2018-01-04
申请号:US15543566
申请日:2016-01-15
申请人: BioNTech RNA Pharmaceuticals GmbH , Universität Stuttgart , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Univers
发明人: Ugur Sahin , Friederike Gieseke , Ronald Backer , Sebastian Kreiter , Roland Kontermann , Klaus Pfizenmaier , Sina Fellermaier , Dafne Müller
IPC分类号: C07K14/525 , A61K38/17
CPC分类号: C07K14/525 , A61K38/1793 , C07K14/52 , C07K2319/70
摘要: The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms. pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
-
-
-
-
-